Clinical Trials Currently Recruiting
Below are current clinical research trials that The University of Vermont Medical Center are currently recruiting for. Ask your doctor to find out if you qualify.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1).
Principal Investigator: James Boyd, MD, the UVM Medical Center
Potential Participants: Click here for more information.
A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS).
Principal Investigator: James Boyd, MD, the UVM Medical Center
Potential Participants: Click here for more information.
A Phase 3, multicenter, randomized, double-blind, placebo controlled study with an open label phase to determine the efficacy and safety of Tozadenant as adjunctive therapy in Levodopa-treated patients with Parkinson's disease experiencing end of dose "wearing off" (TOZ-PD).
Principal Investigator: James Boyd, MD, the UVM Medical Center
Supported By: Biotie, Ltd.
Potential Participants: Click here for more information.
DUOdopa/Duopa in Patients with Advanced Parkinson's Disease (PD) - a Global Observerational Study Evaluating Long-Term Effectiveness (DUOGLOBE)
Principal Investigator: James Boyd, MD, the UVM Medical Center
Supported By: AbbVie, Inc.
Potential Participants: Click here for more information.
A randomized, double-blind, placebo-controlled trial of urate-elevating inosine treatment to slow clinical decline in early Parkinson disease (SURE-PD3)
Principal Investigator: James Boyd, MD, the UVM Medical Center
Supported By: The National Institutes of Health (NIH) and the Michael J. Fox Foundation
Potential Participants: Click here for more information.
Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Principal Investigator: James Boyd, MD, the UVM Medical Center
Supported By: The CHDI Foundation
Potential Participants: Click here for more information.
A Phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with late prodromal and early manifest Huntington disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 (SIGNAL)
Principal Investigator: James Boyd, MD, the UVM Medical Center
Supported By: Vaccinex, Inc.
Potential Participants: Click here for more information.
Primidone Treatment of Essential Tremor
Principal Investigator: James Boyd, MD, the UVM Medical Center
Supported By: The Department of Neurology at the UVM Medical Center
Potential Participants: Click here for more information.
Contact Us
For more information about clinical trials for movement disorders please contact:
Emily Houston, CCRC
Clinical Research Coordinator III
emily [dot] houston
med [dot] uvm [dot] edu (emily[dot]houston[at]med[dot]uvm[dot]edu)
802-656-8974
Jasmine Marsh, MS CCRC
Clinical Research Coordinator II
jasmine [dot] marshuvmhealth [dot] org (jasmine[dot]marsh[at]uvmhealth[dot]org)
802-847-1597